Announcements

17.08.2018

Investigation of Valsartan medicinal products for evidence of active substance contamination – an update

Additional recall of batches in Europe – no products in Switzerland affected to date

12.07.2018

Authorised products containing valsartan as active substance: Overview

Only individual preparations and batches are affected by the precautionary recall

10.07.2018

Änderungen der Liste der dokumentierten traditionellen asiatischen Stoffe

Liste TAS gemäss Anhang 6 Art. 29 Abs.1 (KPAV; SR 812.212.24) und des Vorworts zur Liste TAS

10.07.2018

Changes to the Guidance document on time limits for authorisation applications

The changes to the Guidance document take immediate effect.

06.07.2018

Impurities in valsartan products: risks currently being investigated

Certain preparations containing the active substance valsartan produced by a Chinese manufacturer are in some cases being recalled in Europe

04.07.2018

ICH Assembly in Kobe, Japan, 2 to 7 June 2018

ICH continues membership expansion, and advances harmonisation work in electronic standards and pharmaceutical quality

29.06.2018

Warning regarding eye contact with the veterinary medicinal product Osurnia® ad us.vet.

In both humans and dogs, the ear gel for dogs coming into contact with eyes can result in eye irritation, redness of the eye and in very rare cases corneal ulcers

07.06.2018

Vigilance News Edition 20 – June 2018

Special issue: The history and development of pharma-covigilance in Switzerland over the last three decades

17.08.2018

Investigation of Valsartan medicinal products for evidence of active substance contamination – an update

Additional recall of batches in Europe – no products in Switzerland affected to date

12.07.2018

Authorised products containing valsartan as active substance: Overview

Only individual preparations and batches are affected by the precautionary recall

10.07.2018

Änderungen der Liste der dokumentierten traditionellen asiatischen Stoffe

Liste TAS gemäss Anhang 6 Art. 29 Abs.1 (KPAV; SR 812.212.24) und des Vorworts zur Liste TAS

10.07.2018

Changes to the Guidance document on time limits for authorisation applications

The changes to the Guidance document take immediate effect.

06.07.2018

Impurities in valsartan products: risks currently being investigated

Certain preparations containing the active substance valsartan produced by a Chinese manufacturer are in some cases being recalled in Europe

04.07.2018

ICH Assembly in Kobe, Japan, 2 to 7 June 2018

ICH continues membership expansion, and advances harmonisation work in electronic standards and pharmaceutical quality

29.06.2018

Warning regarding eye contact with the veterinary medicinal product Osurnia® ad us.vet.

In both humans and dogs, the ear gel for dogs coming into contact with eyes can result in eye irritation, redness of the eye and in very rare cases corneal ulcers

07.06.2018

Vigilance News Edition 20 – June 2018

Special issue: The history and development of pharma-covigilance in Switzerland over the last three decades

Last modification 16.11.2017

Top of page